Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders
04 February 2023 - 9:00AM
Business Wire
Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the
“Company”) announced today that it has postponed the Company’s
Special Meeting of Stockholders to be held on February 3, 2023, at
9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern
Time. The postponed Special Meeting will be completely virtual, and
stockholders will be able to attend the special meeting online,
vote and submit questions by visiting
https://www.cstproxy.com/iqmdspac/2023. There will be no change in
the record date as a result of this postponement or the date by
which stockholders must have elected to redeem their public shares,
and proxies tendered prior to the postponed date will not need to
be voted again.
Stockholders may elect to redeem their public shares for a
pro-rata portion of the funds held in the Trust Account, by no
later than February 6, 2023, by tendering their shares either by
delivering their share certificates to the transfer agent or by
delivering their shares electronically using the Depository Trust
Company’s DWAC (Deposit/Withdrawal At Custodian) system. If you
hold your shares in street name, you will need to instruct your
bank, broker or other nominee to withdraw the shares from your
account in order to exercise your redemption rights.
The Company’s stockholders and other interested persons are
advised to read the proxy statement. Stockholders are also able to
obtain copies of the proxy statement and other relevant materials
filed with the Securities and Exchange Commission (the “SEC”),
without charge, at the SEC’s web site at www.sec.gov, or by
directing a request to the Company’s proxy solicitor Morrow Sodali
LLC, at (800) 662-5200 (toll free), or brokers and banks may call
collect (203) 658-9400 You may contact Morrow Sodali by email at
OLIT@investor.morrowsodali.com.
Forward Looking Statements
This press release contains statements that constitute
“forward-looking statements.” No assurance can be given that the
Company will ultimately complete a business combination
transaction. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the Company,
including those set forth in the Risk Factors section of the
Company’s Annual Report on Form 10-K and subsequent reports filed
with the SEC. Copies of these documents are available on the SEC’s
website, at www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230203005391/en/
Brian Ruby, ICR, brian.ruby@icrinc.com
Intelligent Medicine Acq... (NASDAQ:IQMD)
Historical Stock Chart
From May 2024 to Jun 2024
Intelligent Medicine Acq... (NASDAQ:IQMD)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Intelligent Medicine Acquisition Corporation (NASDAQ): 0 recent articles
More Intelligent Medicine Acquisition Corporation News Articles